Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PowerofNowon Mar 01, 2021 7:33pm
122 Views
Post# 32691591

RE:RE:Company to update past 8-months work- a lot in the pipeline

RE:RE:Company to update past 8-months work- a lot in the pipeline KILOFINAL WOOW, respect. I remember you from when Manulife was under $10 per share ! Been around the block
KILOFINAL wrote: Agree. Don't think they would have chosen this specific time to launch the new company and business strategy unless they were well on their way to achieving the results they expect 


Rezjen wrote:

Read between the lines in Today's NR- as this story unfolds to the market, the world will have a solution for Covid-19 
 

More interesting when Ceo says "We intend to become a leader in the race to find a treatment for COVID-19, and we are well positioned to achieve this goal,”

it sounds they are way ahead in the game and knows exactly what they are doing!


long enjoy the ride!!!





<< Previous
Bullboard Posts
Next >>